

L Number	Hits	Search Text	DB	Time stamp
7	2	zmax1 and bone	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/20 17:06
13	3	(WO-200192891-\$ or US-5691153-\$ or WO-200177327-\$).did.	DERWENT	2002/06/20 17:06
-	7	High ADJ bone ADJ mass	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/20 17:00
-	2	(US-5691153-\$ or WO-200192891-\$).did.	DERWENT	2002/06/20 17:02

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number  
**WO 01/77327 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/12**,  
15/11, 5/10, 1/21, C07K 14/705, 14/775, 14/47, 16/28,  
C12Q 1/68, A61K 49/00, G01N 33/50, 33/53, 33/68,  
A01K 67/027, A61K 48/00

(21) International Application Number: PCT/US00/16951

(22) International Filing Date: 21 June 2000 (21.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/543,771 5 April 2000 (05.04.2000) US  
09/544,398 5 April 2000 (05.04.2000) US

(71) Applicant (for all designated States except US):  
**GENOME THERAPEUTICS CORPORATION**  
[US/US]; 100 Beaver Street, Waltham, MA 02453-8443  
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARULLI, John**,  
P. [US/US]; 9 Harris Drive, Southboro, MA 01772 (US).

**LITTLE, Randall, D.** [US/US]; 62A Marshall Street,  
Needham, MA 02192 (US). **RECKER, Robert, R.**  
[US/US]; 3309 South 116th Street, Omaha, NE 68144  
(US). **JOHNSON, Mark, L.** [US/US]; 16216 N. Circle,  
Omaha, NE 68135 (US).

(74) Agents: **REA, Teresa, Stanek**; Burns, Doane, Swecker &  
Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404  
et al. (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: THE HIGH BONE MASS GENE OF 11q13.3

Model for a LDL Receptor-Related protein, Zmax1



(57) Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development and in focal adhesion signaling. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT


(10) International Publication Number  
**WO 01/92891 A2**

- (51) International Patent Classification<sup>7</sup>: **G01N 33/68**
- (21) International Application Number: PCT/US01/16946
- (22) International Filing Date: 25 May 2001 (25.05.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/578,900 26 May 2000 (26.05.2000) US
- (71) Applicants: **GENOME THERAPEUTICS CORPORATION** [US/US]; 100 Beaver Street, Waltham, MA 02453 (US). **CREIGHTON UNIVERSITY SCHOOL OF MEDICINE** [US/US]; Suite 1601, 1601 North 30th Street, Omaha, NE 68178 (US).
- (72) Inventors: **CARULLI, John, P.**; 9 Harris Drive, Southboro, MA 01772 (US). **LITTLE, Randall, D.**; 73 Elm Road #6, Newtonville, MA 02460 (US). **RECKER,**
- Robert, R.**; 3309 South 116th Street, Omaha, NE 68144 (US). **JOHNSON, Mark, L.**; 16216 N. Circle, Omaha, NE 68135 (US).
- (74) Agents: **REA, Teresa, Stanek**; Burns, Doane, Swecker & Mathis, LLP, P.O. Box 1404, Alexandria, VA 22313-1404 et al. (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: REGULATING LIPID LEVELS VIA THE *ZMAX1* OR *HBM* GENE

Model for a LDL Receptor-Related protein, Zmax1



(57) **Abstract:** The present invention relates to the high bone mass (*HBM*) gene, the corresponding wild-type gene (*Zmax1*), and mutants thereof. The genes identified in the present invention are implicated in regulation of physiological lipid levels, and thereby lipid-mediated diseases and conditions. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in lipid level regulation in a subject. In preferred embodiments, the present invention is directed to methods for treating and preventing atherosclerosis, arteriosclerosis cardiovascular disease, atherosclerotic and arteriosclerotic associated conditions.

WO 01/92891 A2